EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H

April K S Salama iD, Victoria Wang, Erin R Macrae, Jong-In Park iD, Helen X Chen, Robert J Gray iD, Lisa M McShane iD, Larry V Rubinstein, David Patton iD, P Mickey Williams, Stanley R Hamilton iD, Deborah K Armstrong iD und 7 weitere

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00338 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von April K S Salama und 18 weiteren Autor:innen. Beteiligte Einrichtung: Duke University, Durham, NC. Hauptthemen laut MEDLINE: Oximes, Pyridones, Imidazoles, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Subprotocol H of the NCI-MATCH trial demonstrated the efficacy of dabrafenib + trametinib in a cohort of patients with BRAF V600 -mutated treatment-refractory solid tumors and myeloma. To confirm the longer-term efficacy and safety of this combination in additional patients, an expansion cohort was added. METHODS Patients with BRAF V600 -mutated malignancies were eligible; patients with cholangiocarcinoma and low-grade serous ovarian cancer were excluded from the expansion cohort. Patients received dabrafenib 150 mg PO twice daily and trametinib 2 mg PO once daily. The primary end point was to evaluate the objective response rate (ORR); secondary end points included progression-free survival (PFS), 6-month PFS, and overall survival (OS). RESULTS The expansion cohort enrolled from October 2020 to January 2023. In total, 36 patients were included in the primary efficacy analysis for the combined cohort, including six patients from the expansion cohort and 30 patients from the original cohort, representing 17 different tumor histologies. Fifty-six percent of patients were female, with a median age of 60. The ORR was 36.1% (13 of 36 [90% CI, 22.9 to 51.2]). The median PFS was 11.4 months, and the median OS was 28.6 months. The 6-month PFS was 67.6% (90% CI, 54.5 to 80.8). In the six molecularly confirmed cases in the expansion cohort, there were two responses, including one complete response in a patient with a pilocytic astrocytoma; an additional two patients without molecular confirmation also had PRs. Three patients (two from the original cohort and one from the expansion cohort) remain on therapy. The safety profile was consistent with previous reports with dabrafenib and trametinib. CONCLUSION This study confirms the clinical benefit of dabrafenib + trametinib in BRAF V600 -mutated solid tumors, supporting the recent tumor-agnostic regulatory approval of this combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OximesPyridonesImidazolesProto-Oncogene Proteins B-rafPyrimidinonesAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsHumansFemaleMiddle AgedMaleAgedMutationAdult

Substanzen

dabrafenibtrametinibOximesPyridonesImidazolesProto-Oncogene Proteins B-rafPyrimidinonesBRAF protein, human

Autor:innen und Institutionen

  • Duke University, Durham, NC.
  • Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA.
  • Columbus Oncology and Hematology Associates, Columbus, OH.
  • Medical College of Wisconsin, Milwaukee, WI.
  • Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
  • Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

ORCID-Profile: April K S Salama, Jong-In Park, Robert J Gray, Lisa M McShane, David Patton, Stanley R Hamilton, Deborah K Armstrong, Barbara A Conley, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty

Förderung

  • NCI NIH HHS

Zitieren

APA

Salama, A. K. S., Wang, V., Macrae, E. R., Park, J. I., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Armstrong, D. K., Tricoli, J. V., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2026). Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. JCO Precision Oncology. https://doi.org/10.1200/po-25-00338

Vancouver

Salama AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, et al. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. JCO Precision Oncology. 2026. doi:10.1200/po-25-00338

BibTeX
@article{Salama2026,
  author = {Salama, April K S and Wang, Victoria and Macrae, Erin R and Park, Jong-In and Chen, Helen X and Gray, Robert J and McShane, Lisa M and Rubinstein, Larry V and Patton, David and Williams, P Mickey and Hamilton, Stanley R and Armstrong, Deborah K and Tricoli, James V and Conley, Barbara A and Arteaga, Carlos L and Harris, Lyndsay N and O'Dwyer, Peter J and Chen, Alice P and Flaherty, Keith T},
  title = {Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00338}
}
Kostenlos starten →